Intervention 1: Intervention group: Ellagic acid, a capsule 200 mg per daily for two months, Manufacturer: Supplement Spot. Intervention 2: Control group: A daily placebo capsule containing wheat flou

3 trials

Sponsors

Qazvin University of Medical Sciences, Mazandaran University of Medical Sciences

Conditions

Major depressive episode. Major depressive disorder, single episodePolycystic ovarian syndrome. Polycystic ovarian syndromeType 2 diabetes. Type 2 diabetes mellitus

Phase 3

Ellagic acid supplementation in women with the poly cystic ovarian syndrome

Active, not recruitingIRCT20141025019669N12

Qazvin University of Medical SciencesPolycystic ovarian syndrome. Polycystic ovarian syndrome

Start: 2019-05-31Target: 60Updated: 2020-05-18

Ellagic acid supplementation effect in patients with type 2 diabetes

RecruitingIRCT20141025019669N13

Qazvin University of Medical SciencesType 2 diabetes. Type 2 diabetes mellitus

Start: 2019-08-31Target: 44Updated: 2019-11-05

Ellagic acid supplementation effect in patients with Major Depressive

RecruitingIRCT20141025019669N15

Mazandaran University of Medical SciencesMajor depressive episode. Major depressive disorder, single episode

Start: 2021-04-04Target: 60Updated: 2021-04-26

Related Papers

Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome.

2021-07-3123 citations

Decreased insulin resistance in diabetic patients by influencing Sirtuin1 and Fetuin-A following supplementation with ellagic acid: a randomized controlled trial

Diabetology & Metabolic Syndrome2021-02-0519 citations